Perspective Therapeutics CATX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $30.63M-50.3% | $61.58M+567% | $9.24M-56.0% | $20.99M-65.2% | ||
| $114.11M-31.0% | $165.34M— | $0— | —— | ||
| $6K-94.8% | $116K-90.0% | $1.17M-14.5% | $1.36M-17.2% | ||
| $148.39M-35.8% | $231.16M+1,273% | $16.84M-68.4% | $53.22M-16.3% | ||
| $76.6M+33.6% | $57.32M+928% | $5.58M+1,403% | $371K-81.2% | ||
| —— | $0-100% | $24.06M— | $0— | ||
| $40M-20.0% | $50M0.0% | $50M— | $0— | ||
| $266.97M-21.7% | $341.1M+248% | $97.89M+68.5% | $58.09M-13.6% | ||
| $20.51M+98.3% | $10.34M+49.7% | $6.91M+348% | $1.54M+81.9% | ||
| $28.68M+57.3% | $18.23M+16.4% | $15.66M+402% | $3.12M+69.0% | ||
| $1.57M-3.4% | $1.63M-3.0% | $1.68M— | $0— | ||
| $59.94M+18.9% | $50.43M+122% | $22.71M+559% | $3.45M+20.6% | ||
| $74K+5.7% | $70K+150% | $28K-80.3% | $142K0.0% | ||
| -$334.84M-44.5% | -$231.72M-52.0% | -$152.44M-43.9% | -$105.93M-11.3% | ||
| $207.03M-28.8% | $290.67M+287% | $75.18M+37.6% | $54.64M-15.1% | ||
| $266.97M-21.7% | $341.1M+248% | $97.89M+68.5% | $58.09M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Perspective Therapeutics's total assets?
- Perspective Therapeutics (CATX) holds $410.8M in total assets, up 24.7% year over year.
- How much debt does Perspective Therapeutics have?
- Perspective Therapeutics carries $4.2M in total debt against $347.4M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Perspective Therapeutics have?
- Perspective Therapeutics holds $54.0M in cash and equivalents.
- Can Perspective Therapeutics cover its short-term obligations?
- Its current ratio is 8.75 — current assets exceed current liabilities.
- Where does Perspective Therapeutics's balance sheet data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
